Comprehensive risk reduction in patients with atrial fibrillation: Emerging diagnostic and therapeutic options. Executive summary of the report from the 3rd AFNET/EHRA consensus conference

Thromb Haemost. 2011 Dec;106(6):1012-9. doi: 10.1160/TH11-07-0517. Epub 2011 Nov 2.

Abstract

There are exciting new developments in several areas of atrial fibrillation (AF) management that carry the hope of improving outcomes in AF patients. This paper is an executive summary that summarises the proceedings from the 3rd AFNET/EHRA consensus conference on atrial fibrillation, held in Sophia Antipolis from November 7th to 9th 2010, shortly after the release of the new ESC guidelines on AF. The conference was jointly organised by the German Atrial Fibrillation competence NETwork (AFNET) and the European Heart Rhythm Association (EHRA). This executive summary report covers four sections: 1. Risk factors and risk markers for AF, 2. Pathophysiological classification of AF, 3. Relevance of monitored AF duration for AF-related outcomes, and 4. Perspectives and needs for implementing better antithrombotic therapy.

Publication types

  • Consensus Development Conference

MeSH terms

  • Atrial Fibrillation / classification
  • Atrial Fibrillation / diagnosis*
  • Atrial Fibrillation / drug therapy*
  • Atrial Fibrillation / physiopathology
  • Biomarkers / metabolism
  • Europe
  • Fibrinolytic Agents / therapeutic use*
  • Humans
  • Practice Guidelines as Topic
  • Risk Factors
  • Risk Reduction Behavior

Substances

  • Biomarkers
  • Fibrinolytic Agents